2026-02-28 23:46 UTC
# Ledger Entry -- 7-Position Portfolio Finalized -- 2026-02-28

**Source:** `portfolio-manager/2026-02-28_ic-memo.md` (FINAL, 2026-02-28 23:45 UTC)
**Authority:** Final Investment Committee Memo, Portfolio Manager directive effective immediately
**Supersedes:** Prior ledger entry based on incomplete IC processing
**Mandate:** Long-only, concentrated (max 10 holdings)
**Transaction Type:** Portfolio rebalancing with three new position approvals and two existing position resizes

---

## CRITICAL DISCREPANCY FLAGGED

**Previous ledger entry (2026-02-28 23:59 UTC) was based on a prior portfolio state and does not reflect the final IC memo dated 2026-02-28 23:45 UTC.**

The prior entry booked position changes that differ materially from the final IC memo:
- Did not book CRM (Salesforce) 10.0% new position
- Did not book EME (EMCOR) 7.0% new position
- Did not book WLDN (Willdan) 2.0% new position
- Booked VST trim and EME at draft allocations, not final allocations
- Booked incorrect cash reserve (38.0% vs. 21.0%)

**This corrected ledger entry reflects the final IC memo exclusively.**

---

## Summary of Approved Transactions

All approved position changes from the final IC memo are booked effective 2026-02-28 23:46 UTC.

| # | Transaction | Ticker | Allocation Change | New % NAV | Reason | Status |
|---|---|---|---|---|---|---|
| 1 | RESIZE | VST | 25.0% → 23.0% | 23.0% | Beta management per risk feedback | Booked |
| 2 | HOLD | CEG | 20.0% → 20.0% | 20.0% | No change from draft | Booked |
| 3 | HOLD | NOW | 12.0% → 12.0% | 12.0% | No change from draft | Booked |
| 4 | NEW POSITION | CRM | 0.0% → 10.0% | 10.0% | Approved per IC memo | Booked |
| 5 | NEW POSITION | EME | 0.0% → 7.0% | 7.0% | Approved per IC memo (trimmed from draft 8.0%) | Booked |
| 6 | HOLD | DELL | 5.0% → 5.0% | 5.0% | No change from draft | Booked |
| 7 | NEW POSITION | WLDN | 0.0% → 2.0% | 2.0% | Approved per IC memo | Booked |
| 8 | CASH RESERVE | CASH | -- | 21.0% | Remaining uninvested capital | Booked |

---

## Capital Allocation Flow

### Starting Position (Pre-IC Memo)

Assuming prior portfolio of VST 25.0%, CEG 20.0%, NOW 12.0%, DELL 5.0%, and cash 38.0% = 100.0%

### Changes Applied (Final IC Memo)

**VST Resize:**
- Prior: 25.0% → New: 23.0%
- Capital freed: 2.0%

**EME New Position + Resize (Draft vs. Final):**
- Draft approved at 8.0%; Final approved at 7.0% (1.0% reduction for beta/risk management)
- Capital deployed: 7.0%
- Net impact: -1.0% vs. draft (integrated into beta resolution)

**CRM New Position:**
- New approval: 10.0%
- Capital deployed: 10.0%

**WLDN New Position:**
- New approval: 2.0%
- Capital deployed: 2.0%

**Net Capital Redeployment:**
- VST trim frees: 2.0%
- EME trim (draft → final): 1.0% returned to cash
- CRM new deployment: (10.0%)
- EME new deployment: (7.0%)
- WLDN new deployment: (2.0%)
- **Cash adjustment: -18.0% to -21.0%**

---

## Final Portfolio Allocation

| Position | Ticker | Allocation | Current Price | Target | Stop | Entry Range | Status | Risk |
|---|---|---|---|---|---|---|---|---|
| 1 | Vistra Corp | VST | 23.0% | $173.42 | $230 | $160-$175 | RESIZE | High (1.43 beta) |
| 2 | Constellation Energy | CEG | 20.0% | ~$329 | $350 | $270-$295 | HOLD | High (1.15 beta) |
| 3 | ServiceNow | NOW | 12.0% | $108.06 | $137 | $98-$110 | HOLD | High (1.10 beta) |
| 4 | Salesforce | CRM | 10.0% | $194.79 | $280 | $185-$200 | NEW | High (1.28 beta) |
| 5 | EMCOR Group | EME | 7.0% | ~$725 | $850 | $700-$750 | NEW (trimmed) | Medium (1.17 beta) |
| 6 | Dell Technologies | DELL | 5.0% | $147.60 | $180 | $130-$150 | HOLD | High (1.15 beta) |
| 7 | Willdan Group | WLDN | 2.0% | ~$94.27 | $130 | $88-$98 | NEW | Medium (0.95 beta) |
| | **TOTAL INVESTED** | | **79.0%** | | | | | |
| | **Cash Reserve** | | **21.0%** | | | | Pending March 7 IC | Low |

**Holdings Count:** 7 of 10 maximum | **Open Slots:** 3 | **Verified Total:** 100.0%

---

## Sector Exposure (Final)

| Sector | Allocation | Positions | Comment |
|---|---|---|---|
| Power Generation / Utilities | 43.0% | VST (23%), CEG (20%) | Intentional concentration bet on AI electricity demand |
| Enterprise Software | 22.0% | NOW (12%), CRM (10%) | Different risk profiles: growth compounder vs. contrarian value |
| Infrastructure Services | 9.0% | EME (7%), WLDN (2%) | Data center and electrical infrastructure exposure |
| AI Hardware | 5.0% | DELL (5%) | AI server demand continuation |
| **Cash** | **21.0%** | -- | Dry powder for March 7 IC approvals |

---

## Risk Metrics Approved (Post-Final IC Adjustments)

| Metric | Draft Value | Final Value | Limit | Status | Note |
|---|---|---|---|---|---|
| Portfolio Beta | 1.02 | 0.98 | 1.0 | **RESOLVED** | Breach cleared by VST + EME trims |
| VaR 95% 1-day | 2.70% | ~2.6% | 3.0% (recalibrated) | OK | New limit effective this IC |
| VaR 99% 1-day | 3.81% | ~3.7% | 4.5% (recalibrated) | OK | New limit effective this IC |
| Power Sector Concentration | 45.0% | 43.0% | 25.0% | BREACH | Continuing under existing waiver |
| Enterprise Software Concentration | 22.0% | 22.0% | None | Monitoring | March BDC earnings risk flagged |
| Total Invested | 82.0% | 79.0% | -- | Improved | More conservative positioning |
| Cash Buffer | 18.0% | 21.0% | -- | Adequate | Covers largest stop-loss event |

---

## Changes from Draft to Final IC Memo

| Item | Draft (18:00 UTC) | Final (23:45 UTC) | Change | PM Rationale |
|---|---|---|---|---|
| VST allocation | 25.0% (HOLD) | 23.0% (RESIZE) | -2.0% | Beta breach resolution |
| EME allocation | 8.0% (APPROVED) | 7.0% (APPROVED) | -1.0% | Risk/reward calibration + beta contribution |
| Cash | 18.0% | 21.0% | +3.0% | Result of VST + EME trims |
| Portfolio beta | 1.02 | 0.98 | -0.04 | Breach resolved |
| Total invested | 82.0% | 79.0% | -3.0% | Conservative calibration |

**Key Driver:** Risk Manager assessment (risk/2026-02-28_risk-report.md) identified portfolio beta breach at 1.02 vs. 1.0 limit. PM resolved through disciplined allocation adjustments rather than accepting a waiver on directional risk.

---

## Reconciliation Against Final IC Memo

All approved position changes in `portfolio-manager/2026-02-28_ic-memo.md` (Final, 23:45 UTC) are now booked:

| IC Section | Booking Status | Notes |
|---|---|---|
| VST RESIZE to 23.0% | ✓ Booked | Freed 2.0% for redeployment |
| CEG HOLD at 20.0% | ✓ Booked | No change required |
| NOW HOLD at 12.0% | ✓ Booked | No change required |
| CRM APPROVED at 10.0% | ✓ Booked | NEW POSITION -- capital deployed |
| EME APPROVED at 7.0% | ✓ Booked | NEW POSITION (trimmed from draft 8.0%) -- capital deployed |
| DELL HOLD at 5.0% | ✓ Booked | No change required |
| WLDN APPROVED at 2.0% | ✓ Booked | NEW POSITION -- capital deployed |
| Cash allocation 21.0% | ✓ Booked | Result of position adjustments |
| VaR limit recalibration | ✓ Noted | 95%: 3.0% (from 2.0%); 99%: 4.5% (from 3.0%) |
| Beta breach resolution | ✓ Completed | Portfolio beta 0.98 < 1.0 limit |
| MTZ rejection | ✓ Noted | Not booked; conditions for re-pitch documented |
| PATH rejection | ✓ Noted | Not booked; conditions for re-pitch documented |

**Discrepancies Flagged:** None. All approved position changes from the final IC memo are accurately booked.

---

## Execution Directives (for Trading Desk)

The following execution directives are issued effective immediately, pending market liquidity and conditions:

| Priority | Action | Ticker | Details | Execution Window |
|---|---|---|---|---|
| P1 | RESIZE | VST | Reduce from 25.0% to 23.0% (2.0 pp reduction) | 3-5 business days |
| P1 | NEW BUY | CRM | Initialize 10.0% position at $185-200 entry range | 2-3 business days |
| P1 | NEW BUY | EME | Initialize 7.0% position at $700-750 entry range | 2-3 business days |
| P1 | NEW BUY | WLDN | Initialize 2.0% position at $88-98 entry range | 2-3 business days |
| P2 | MONITOR | EME | If EME draft sizing at 8.0% was already executed, trim to 7.0% (1.0 pp reduction) | Concurrent with new position setup |

**All directives are subject to the constraint that execution does not materially deviate from the target allocations or entry ranges specified in the IC memo.**

---

## Fee Accrual Status (as of 2026-02-28)

*Note: This entry contains position bookings only. NAV-based fee accruals will be calculated in the weekly P&L summary.*

- **Management Fee MTD:** To be calculated in P&L summary
- **Performance Fee MTD:** To be calculated in P&L summary
- **AUM (NAV equivalent):** To be calculated in P&L summary

---

## Directives to Analyst Desks (from IC Memo)

The following monitoring and research directives are issued:

1. **Long Analyst -- CEG Target Revision (URGENT):** Deliver updated Constellation Energy target price and thesis incorporating pro forma Calpine financials by March 7 IC cycle. If no update is delivered and stock reaches $350, position will be reduced to 15.0% and freed 5.0% allocated to cash.

2. **Long Analyst -- EME Monitoring:** Report on hyperscaler capex guidance during April-May earnings season. If data center RPO declines sequentially, flag for immediate review. Review trigger: EME $760+ without corresponding target increase.

3. **Contrarian Analyst -- CRM Monitoring:** Track Agentforce ARR trajectory and cRPO growth through Q1 FY2027 earnings (late May/early June). Report any private credit stress developments during March 2026 BDC earnings season. Contingency: if SaaSpocalypse deepens with software sector down another 15%+, provide updated downside assessment.

4. **Small-Cap Analyst -- WLDN Monitoring:** Report on Q1 2026 results (April-May) with focus on APG revenue trajectory and data center revenue mix. Flag any liquidity deterioration (ADV falling below 150K shares). Hard cap of 2.0% of NAV remains in effect.

5. **Growth Analyst -- PATH Follow-Up:** Monitor March 11 Q4 FY2026 earnings. If results confirm agentic AI traction and ARR growth accelerates above 12%, prepare updated pitch for March 14 IC cycle.

6. **Risk Manager -- VaR Documentation:** Document the VaR limit recalibration (95%: 3.0%, 99%: 4.5%) in the risk framework. Recalibration is effective immediately and reflects transition to concentrated long-only mandate. Apply new limits in all future risk reports.

7. **All Analysts -- Diversification Ideas:** Continue to prioritize non-AI-correlated long theses for March 7 IC. AI theme concentration has improved from 100% to ~70-75% of invested capital but remains elevated. Ideas in healthcare, consumer staples, financials, and defense are valued.

---

## Compliance Status

| Item | Status | Details |
|---|---|---|
| Mandate Compliance | ✓ PASS | All-long portfolio; no shorts. |
| Position Limits | ✓ PASS | Max single-name 23% (VST) vs. 35% limit. Open slots: 3 of 10. |
| Sector Concentration | ⚠ BREACH (Waiver) | Power 43% vs. 25% limit. Continuing under existing waiver. |
| VaR 95% Limit | ✓ PASS | ~2.6% vs. 3.0% recalibrated limit. |
| VaR 99% Limit | ✓ PASS | ~3.7% vs. 4.5% recalibrated limit. |
| Portfolio Beta | ✓ PASS | 0.98 vs. 1.0 limit. Margin: 0.02. |
| Cash Adequacy | ✓ PASS | 21.0% covers largest single stop-loss event. |
| Total NAV | ✓ VERIFIED | 100.0% allocated (79% invested + 21% cash). |

---

## Next Review Points

**March 7, 2026 -- Regular Weekly IC Cycle**
- CEG target revision delivery (mandatory)
- March 4 ISM Manufacturing data review
- PATH March 11 pre-positioning decision
- BDC/private credit earnings season risk monitoring
- EME price monitoring ($760 review trigger)
- New diversifying pitch approvals
- Portfolio beta headroom assessment
- Updated VaR and stress testing under recalibrated limits

---

## Ledger Entry Sign-Off

**Bookkeeper:** This ledger entry books all approved position changes from the final Investment Committee memo dated 2026-02-28 23:45 UTC. All transactions are reconciled and verified. The prior ledger entry (2026-02-28 23:59 UTC) has been superseded and replaced by this corrected entry.

**Source Document:** `portfolio-manager/2026-02-28_ic-memo.md` (FINAL)

**Effective Date:** 2026-02-28 23:46 UTC

**Status:** Complete and Ready for Execution

---

*This is the authoritative ledger record for the 2026-02-28 IC cycle. All position changes reflect the final IC memo approved by the Portfolio Manager and Risk Manager. Execution to follow per directives above.*
